Key Points
- Insider sale: Chris Francis sold 9,375 WVE shares on Jan. 2 at an average price of $16.03 (~$150,281), cutting his stake to 25,000 shares (a 27.27% decrease) after a prior Dec. 8 sale of 441,031 shares for about $6.43M.
- Analyst optimism: Wall Street is broadly positive with 13 Buy ratings and one Sell, recent target upgrades from multiple firms, and an average price target of $31.67 (several targets raised into the $30–40 range).
- Company fundamentals: WAVE is a clinical-stage genetic medicines company with a $2.53B market cap but reported a quarterly loss (EPS -$0.32), missed revenue expectations, and negative margins.
WAVE Life Sciences Ltd. (NASDAQ:WVE - Get Free Report) insider Chris Francis sold 9,375 shares of the company's stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $16.03, for a total value of $150,281.25. Following the completion of the transaction, the insider directly owned 25,000 shares in the company, valued at approximately $400,750. This trade represents a 27.27% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Chris Francis also recently made the following trade(s):
- On Monday, December 8th, Chris Francis sold 441,031 shares of WAVE Life Sciences stock. The stock was sold at an average price of $14.57, for a total value of $6,425,821.67.
WAVE Life Sciences Trading Up 1.0%
Shares of WVE opened at $15.15 on Wednesday. The firm has a market cap of $2.53 billion, a P/E ratio of -20.20 and a beta of -1.82. WAVE Life Sciences Ltd. has a 12-month low of $5.28 and a 12-month high of $21.73. The company's 50-day moving average price is $11.78 and its 200 day moving average price is $9.26.
WAVE Life Sciences (NASDAQ:WVE - Get Free Report) last announced its earnings results on Monday, November 10th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.02). WAVE Life Sciences had a negative return on equity of 75.61% and a negative net margin of 111.64%.The company had revenue of $7.61 million for the quarter, compared to analysts' expectations of $9.85 million. Equities research analysts forecast that WAVE Life Sciences Ltd. will post -1.14 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several analysts recently weighed in on WVE shares. Canaccord Genuity Group lifted their target price on shares of WAVE Life Sciences from $19.00 to $40.00 and gave the company a "buy" rating in a report on Monday, December 8th. Raymond James Financial restated an "outperform" rating and set a $21.00 price target on shares of WAVE Life Sciences in a research report on Monday, December 8th. HC Wainwright lifted their price objective on WAVE Life Sciences from $22.00 to $30.00 and gave the company a "buy" rating in a research note on Friday, December 19th. Wedbush increased their target price on WAVE Life Sciences from $20.00 to $33.00 and gave the stock an "outperform" rating in a research note on Friday, December 12th. Finally, Cantor Fitzgerald raised their target price on WAVE Life Sciences from $12.00 to $34.00 and gave the company an "overweight" rating in a report on Tuesday, December 9th. Thirteen equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $31.67.
Get Our Latest Research Report on WAVE Life Sciences
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the stock. Virtus Investment Advisers LLC increased its holdings in WAVE Life Sciences by 10.2% during the 2nd quarter. Virtus Investment Advisers LLC now owns 13,060 shares of the company's stock worth $85,000 after purchasing an additional 1,210 shares during the period. Ameritas Investment Partners Inc. boosted its stake in shares of WAVE Life Sciences by 18.7% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 11,444 shares of the company's stock valued at $74,000 after buying an additional 1,802 shares during the period. Velan Capital Investment Management LP grew its position in shares of WAVE Life Sciences by 15.4% during the second quarter. Velan Capital Investment Management LP now owns 15,000 shares of the company's stock worth $98,000 after buying an additional 2,000 shares in the last quarter. Matisse Capital increased its stake in shares of WAVE Life Sciences by 17.9% during the third quarter. Matisse Capital now owns 13,193 shares of the company's stock worth $97,000 after buying an additional 2,000 shares during the period. Finally, Teacher Retirement System of Texas increased its stake in shares of WAVE Life Sciences by 8.2% during the second quarter. Teacher Retirement System of Texas now owns 28,955 shares of the company's stock worth $188,000 after buying an additional 2,206 shares during the period. 89.73% of the stock is owned by institutional investors and hedge funds.
WAVE Life Sciences Company Profile
(
Get Free Report)
WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.
The company's pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington's disease, as well as early-stage cardiovascular and liver indications.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
